Track Pacific Biosciences of California, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Pacific Biosciences of California, Inc. PACB · Stock Open Pacific Biosciences of California, Inc. in new tab

1.96 USD
EPS
-0.42
P/B
-10.13
ROE
-929.32
Beta
2.20
Target Price
2.78 USD
Pacific Biosciences of California, Inc. logo

Pacific Biosciences of California, Inc.

🧾 Earnings Recap – Q3 2026

PacBio shares fell 4.7% after earnings, as higher revenue and instrument placements were tempered by a still-modest consumables increase and management’s acknowledgement of uneven capital purchasing, particularly in the Americas. The SPRQ-Nx transition is progressing, but customers are still validating workflows and establishing reorder patterns, leaving the timing of higher utilization uncertain.

  • Q3 revenue was $40.6 million, up from $38.4 million a year earlier and $39 million in Q2.
  • Consumables revenue rose to $20.8 million from $20.1 million sequentially; Revio pull-through was approximately $204,000, and management maintained its full-year range of $200,000–$225,000 per system.
  • SPRQ-Nx accounted for over half of Revio consumable revenue, and two-thirds of the Revio installed base had opted into the software upgrade by quarter-end. Management said customers are still validating multi-use workflows and working through inventory.
  • Instrument revenue increased 17% year over year to $13.2 million. PacBio placed 15 Revio systems and 35 Vega systems; Vega placements were up 35% sequentially.
  • Management cited uneven capital purchasing, especially in the Americas, and expects more SPRQ-Nx reorders in coming months, with higher pull-through anticipated in 2027 and beyond.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 9, 2027
EPS-0.42
Book Value-0.20
Price to Book-10.13
Debt/Equity29855.79
% Insiders8.799%
Growth
Revenue Growth0.06%
Estimates
Forward P/E-4.95
Forward EPS-0.40
Target Mean Price2.78

DCF valuation

Model fair value for Pacific Biosciences of California, Inc. (PACB)
Result
Sign in to run the valuation for PACB.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Buy · mean target 2.78 USD (low 2.00, high 3.00) · as of 12 Nov 2026
Low 2.00
Mean 2.78
High 3.00
Price 1.96
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Pacific Biosciences of California, Inc. Logo Pacific Biosciences of California, Inc. Analysis (PACB)

United States Health Care Official Website Stock

Is Pacific Biosciences of California, Inc. a good investment? Pacific Biosciences of California, Inc. (PACB) is currently trading at 1.96 USD. Market analysts have a consensus price target of 2.78 USD. This suggests a potential upside from current levels.

Earnings Schedule: Pacific Biosciences of California, Inc. is expected to release its next earnings report on Feb. 9, 2027. The market consensus estimate for Forward EPS is -0.40.

Investor FAQ

Does Pacific Biosciences of California, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Pacific Biosciences of California, Inc.?

Pacific Biosciences of California, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 9, 2027. The company currently has a trailing EPS of -0.42.

Company Profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Exchange Ticker
NMS (United States) PACB
FRA (Germany) P09.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion